Abstract: The present invention generally relates to combinations for use in therapeutic systems and antibody dosage regimens, and uses thereof. Also described herein is a model for predicting if a therapeutic antibody binding to a human target will be associated with a tolerability issue in connection with intravenous administration and/or for predicting if pre-treatment, altered administration route or modification of the antibody can prevent a tolerability issue associated with intravenous administration to a human of the therapeutic antibody. The model comprises administering the antibody intravenously or intraperitoneally to mice and observing the mice immediately after the administration for any transient display of the macroscopic symptoms isolation and decreased activity.

Abstract: A process for removal of aluminium and iron in the recycling of rechargeable batteries comprising providing a leachate from black mass, adding phosphoric acid (H3PO4) to said leachate and adjusting the pH to form iron phosphate (FePO4) and aluminium phosphate (AlPO4), precipitating and removing the formed FePO4 and AlPO4, and forming a filtrate for further recovery of cathode metals, mainly NMC-metals and lithium.

Abstract: A process for removal of aluminium and iron in the recycling of rechargeable batteries comprising providing a leachate from black mass, adding phosphoric acid (H3PO4) to said leachate and adjusting the pH to form iron phosphate (FePO4) and aluminium phosphate (AlPO4), precipitating and removing the formed FePO4 and AlPO4, and forming a filtrate for further recovery of cathode metals, mainly NMC-metals and lithium.

Abstract: Described is the combined use of a first antibody molecule that specifically binds FcyRIIb via its Fab region and that binds an Fey receptor via its Fc region, and a second antibody molecule that specifically binds PD-1 and that binds at least one Fey receptor via its Fc region, in the treatment of cancer in a patient having tumor infiltrating T lymphocytes with a medium or high PD-1 expression, as well as pharmaceutical compositions and kits comprising these two antibody molecules, and methods of treating cancer using these two antibodies. Described is also a diagnostic test for identification of patients benefitting from the treatment described herein.

Abstract: A process for removal of aluminium and iron in the recycling of rechargeable batteries comprising providing a leachate from black mass, adding phosphoric acid (H3PO4) to said leachate and adjusting the pH to form iron phosphate (FePO4) and aluminium phosphate (AlPO4), precipitating and removing the formed FePO4 and AlPO4, and forming a filtrate for further recovery of cathode metals, mainly NMC-metals and lithium.